[Atherogenic dyslipidemia and residual risk. State of the art in 2014]

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Metabolic syndrome, obesity, and type 2 diabetes pose significant global health challenges, increasing cardiovascular disease burden.
• Atherogenic dyslipidemia is a key modifiable factor in residual cardiovascular risk, characterized by an imbalance in lipoproteins.
• Current management strategies for atherogenic dyslipidemia often require pharmacological intervention beyond lifestyle changes.

Purpose of the Study:

• To highlight atherogenic dyslipidemia as a critical target for reducing residual cardiovascular risk.
• To emphasize the role of pharmacological approaches, particularly fibrates, in managing atherogenic dyslipidemia.
• To discuss the combination of fibrates with statins for enhanced lipid management.

Main Methods:

• Review of existing literature and guidelines on metabolic syndrome, dyslipidemia, and cardiovascular disease.
• Analysis of the role of atherogenic dyslipidemia in residual cardiovascular risk.
• Evaluation of pharmacological treatment options, focusing on fibrates and statins.

Main Results:

• Atherogenic dyslipidemia is a significant contributor to residual cardiovascular risk.
• Fibrates are a primary pharmacological option for combination therapy.
• Combining fibrates with statins can effectively reduce non-HDL cholesterol levels.

Conclusions:

• Effective management of atherogenic dyslipidemia is crucial for mitigating cardiovascular risk.
• Pharmacological interventions, especially fibrate-statin combinations, offer a valuable strategy to improve patient outcomes.
• Further research and clinical application of these strategies are warranted.